HHS Allows Unapproved Peptides
RFK Jr.'s HHS says it will not penalize compounders making six popular peptides.
October 28, 2026 · Updated Oct 28, 6:46pm ET
The New York TimesRFK Jr. to Allow Broad Use of Unapproved Peptide Injections
Wall Street JournalRFK Jr. Allows Unapproved Peptides on the Market
CNNRFK Jr. acts to ease access to unproven peptides despite opposition from FDA scientists
ABC NewsFDA scientists opposed the Trump administration's effort to ease peptides access
PBS NewsHourAP report: FDA scientists opposed the Trump administration's move to ease peptides access
The HillHHS to allow sale of unapproved peptides under review
Boston GlobeRFK Jr. eases access to unproven peptides despite opposition from FDA scientists
ARS TechnicaPeptide peddlers cheer as RFK Jr. unilaterally grants access, overruling FDA
TIME MagazineThe Peptide Rush Has Begun
UPIRFK Jr. to allow use of unapproved peptide injections, bypassing FDA rules
The GuardianFDA scientists opposed Trump administration’s move to ease peptide access
STAT NewsHHS moves to allow compounding of some unapproved peptides
Scientific AmericanRFK, Jr., loosens restrictions for six popular peptides, bypassing the FDA
NBC NewsRFK Jr. takes shortcut to make some unapproved peptides available for use
Raw StoryScientists rebel over RFK Jr.'s 'unproven' health product access plan: report
NPRTrump administration will allow pharmacies to make popular peptides
MarketWatchThe U.S. government will no longer penalize American companies for making six popular peptides
42%
Left · 8
58%
Center · 11
0%
Right · 0
Pano rates the coverage Mostly Left.
What happened
HHSDepartment of Health and Human ServicesUnited States federal executive department said it would allow eligible providers to compound six unapproved peptides without federal penalties. The enforcement-discretion policy covers state-licensed pharmacies, federal facilities and licensed physicians making BPC-157, TB-500, Epitalon, KPV, MOTS-c and Semax. The policy does not approve the peptides or find them safe and effective. They have not gone through FDA review, and FDA scientists said evidence was insufficient and raised safety concerns. HHS first sought a formal rule, then shifted after FDA staff objected. An FDA advisory committee recommended allowing compounding after a July review, while FDA scientific staff opposed it. HHS said the move would expand access and steer consumers from gray- and black-market products. The temporary policy is open for public comment for two weeks.
How the left told it
Left-leaning outlets framed the decision as a safety fight over wellness treatments promoted faster than the science behind them. The New York Times said the policy would allow broad access to unapproved injections popularized online, alarming drug-safety experts. CNN emphasized claims from six people familiar with the decision that FDA scientists had little input and opposed the change.
How the right told it
Right-leaning outlets we track didn't cover this story.
HHS Peptide Compounding Policy
Part of the storyline · Storyline →- Oct 29HHS Waives Enforcement For Six PeptidesMostly Center
- Oct 28HHS Allows Unapproved Peptides (this story)Mostly Left
